Transthyretin amyloidoses;Les amyloses à transthyrétine

Revue de Medecine Interne

Volumn 28, Issue 5, 2007, Pages 306-313

  Magy Bertrand, N ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Amyloid; Mutation; Senile; Transthyretin

Indexed keywords

AMYLOID; PREALBUMIN;

AMYLOID NEUROPATHY; AMYLOIDOSIS; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; FAMILIAL DISEASE; GENE MUTATION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY AMYLOIDOSIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN STRUCTURE; SHORT SURVEY; VITREOUS DISEASE; GENE THERAPY; METABOLISM; REVIEW;

AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; GENE THERAPY; HUMANS; LIVER TRANSPLANTATION; PREALBUMIN; PROGNOSIS;

EID: 34247132570     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.01.004     Document Type: Short Survey

References (38)

1. Virchow R. Amyloid degeneration. Cellular pathology. Lecture XVII delivered in the pathological institute of Berlin on April 17, 1858 (1860), John Churchill, London
2. Sipe J.D. Revised nomenclature for serum amyloid A (SSA). Nomenclature comittee of the international society of amyloidosis. Part 2. Amyloid Int J Exp Clin Invest 6 (1999) 67-70
3. Andrade C. A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvment of the peripheral nerves. Brain 75 (1952) 408-428
4. Ohmori H., Ando Y., Makita Y., Onouchi Y., Nakajima T., Saraiva M.J.M., et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J. Med. Genet. 41 (2004) e51
5. Bittencourt P.I., Couto C.A., Clemente C., Farias A.Q., Palacios S.A., Mies S., et al. Phenotypic expression of familial polyneuropathy in Brazil. Eur. J. Neurol. 12 (2005) 289-293
6. Ando Y., Nakamura M., and Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 62 (2005) 1057-1062
7. Holmgren G., Costa P.M., Andersson C., Asplund K., Steen L., Beckman L., et al. Geographical distribution of TTR met30 carriers in northern Sweden : discrepancy between carrier frequency and prevalence rate. J. Med. Genet. 31 (1994) 351-354
8. Cornwell III G.G., Murdoch W.L., Kyle R.A., Westermark P., and Pitkanen P. Frequency distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am. J. Med. 75 (1983) 618-623
9. Westermark P., Johansson B., and Natvig J.B. Seneil cardiac amyloidosis : evidence of two different amyloid substances in the ageing heart. Scand. J. Immunol. 10 (1979) 303-308
10. Hodkinson H.M., and Pomerance A. The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. Q. J. Med. 46 (1977) 381-387
11. Ng B., Connors L.H., Davidoff R., Skinner M., and Falk R.H. Senile systemic amyloidosis presenting with heart failure: a comparison with light-chain amyloidosis. Arch. Intern. Med. 27 (2005) 1425-1429
12. Robbins J. Thyroxine-binding proteins. Prog. Clin. Biol. Res. 5 (1976) 331-355
13. Wallace M.R., Naylor S.L., Kluve-Beckerman B., Long G.L., Mc Donald L., Shows T.B., et al. Localisation of the human prealbumin gene to chromosome 18. Biochem. Biophys. Res. Commun. 129 (1985) 753-758
14. Alves I.L., Divino C.M., Schussler G.C., Atland K., Almeida M.R., Pahla J.A., et al. Thyroxine binfding in a TTR 119Met kindred. J. Clin. Endocrinol. Metab. 77 (1993) 484-488
15. Ando Y. New therapeutic aprroaches for familial amyloidotic polyneuropathy (FAP). Amyloid. Int. J. Exp. Clin. Invest. 10 suppl 1 (2003) 55-66
16. Redondo C., Damas A.M., Oloffson A., Lundgren E., and Saraiva M.J.M. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J. Mol. Biol. 304 (2000) 461-470
17. Magy N., Liepnieks J.J., Gil H., Kantelip B., Dupond J.L., Kluve-Beckerman B., et al. A transthyretin mutation (Tyr78Phe) mutation associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis. Amyloid Int J Exp Clin Invest 10 (2003) 29-33
18. Westermark P., Sletten K., Johansson B., and Cornwell III G.G. Fibril in systemic senile amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87 (1990) 2843-2845
19. Magy N., Liepnieks J.J., Kluve-Beckerman B., and Benson M.D. Aymloid-enhancing factor mediates amyloid formation on fibroblasts via a nidus/template mechanism. Arthritis Rheum. 48 (2003) 1430-1437
20. Adams D., and Said G. In: Grateau G., Benson M.D., and Delpech M. (Eds). Neuropathies amyloïdes (2000), Médecine-Sciences Flammarion, Paris 179-192
21. Falk R.H. Diagnostic and management of the cardiac amyloidoses. Circulation 112 (2005) 2047-2060
22. Hongo M., Hirayama J., Fujii T., Yamada H., Okubo M., and Kusama S. Early identification of amyloid heart disease by technetium-99m pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. Am. Heart J. 113 (1987) 654-662
23. Sandgren O. Ocular amyloidosis with special reference to the hereditary forms with vitreous involvement. Surv. Ophtalmol. 40 (1995) 173-196
24. Puchtler H., Sweat F., and Levine M. On the binding of Congo Red by amyloid. J. Histochem. Cytochem. 10 (1962) 355-363
25. Benson M.D., Yazaki M., and Magy N. Laboratory assessment of transthyretin amyloidosis. Clin. Chem. Lab. Med. 40 (2002) 1262-1265
26. Atland K., and Banzhoff A. Separation by hybrid isoelectric focusing of normal human transthyretin (prealbumin) and a variant with a methionine for valine substitution associated with familial amyloidotic polyneuropathy. Electrophoresis 7 (1986) 529-533
27. Gillmore J.D., Hawkins P.N., and Pepys M.B. Amyloidosis: a review of recent diagnosis and therapeutics developments. Br. J. Haematol. 99 (1997) 245-256
28. Hazenberg B.P., van Rijswijck M.H., Piers D.A., Lub-de Hooge M.N., Vellenga E., Haagsma E.B., et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 119 355 (2006) 15-24
29. Gertz M.A., Kyle R.A., and Thibodeau S.N. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin. Proc. 67 (1992) 428-440
30. Holmgren G., Steen L., Ekstedt J., Groth C.G., Ericzon B.G., Eriksson S., et al. Biochemical effect of liver transplantation in two Swedisch patients with familial amyloidotic polyneuropathy (FAP-met30). Clin. Genet. 40 (1991) 242-246
31. Stangou A.J., and Hawkins P.N. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr. Opin. Neurol. 17 (2004) 615-620
32. Herlenius G., Wilczek H.E., Larsson M., and Ericzon B.G. Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation 77 (2004) 64-71
33. Yazaki M., Tokuda T., Nakamura A., Higashikata T., Koyama J., Higuchi K., et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type trnasthyretin. Biochem. Biophys. Res. Commun. 274 (2000) 702-706
34. Nakamura A., and Ando Y. Application of gene therapy for familial amyloidotic polyneuropathy. Expert Opin. Biol. Ther. 4 (2004) 1621-1627
35. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., and Gallimore J.R. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002) 231-233
36. Berk J., Bisbee A., Kelly J., Dyck P., Falk R., Ando Y., et al. Clinical trial for TTR amyloidosis using diflunisal. Amyloid Int. J. Exp. Clin. Invest (2006), XIth International Symposium on Amyloidosis, Informa London 11
37. Labaudinière R., Bulawa C.E., Wang L., Devit M., and Packman J.N. Fx-1006A, a novel potent and selective stabilizer for the treatment of TTR amyloidosis. Amyloid Int. J. Exp. Clin. Invest (2006), XIth International Symposium on Amyloidosis, Informa London 11
38. Ancsin J.B., and Kisilevsky J.B. The heparin/heparan sulfate binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274 (1999) 7172-7181